A recent paper proposes a generic antitumor therapy based on the intratumor delivery of mRNA that codes for the necroptosis effector MLKL, showing that this intervention stalls primary tumor growth and protects against distal and disseminated tumor formation in syngeneic mouse melanoma and colon carcinoma models [158]. This evidence concerns the gene MLKL and colon carcinoma.